ABSTRACT: Background. Arterial thromboses following cisplatin-based chemotherapy in head and neck cancers are extremely rare and devastating complication. Methods and Results. A 54-year-old male smoker had an acute history of left lower limb pain and calf claudication 3 days following the first cycle of cisplatin-based chemotherapy given concurrently with radiotherapy for squamous cell carcinoma of the base of tongue. CT angiography showed extensive abdominal aortic thrombus along with involvement of left common iliac, saphenopopliteal, and tibeal arteries as well as moderate stenosis in the proximal segments of left anterior descending and right coronary artery. We suggest that endothelial damage and hypercoaguable state secondary to cisplatin may have induced severe arterial and coronary thrombosis. Conclusions. This is the first reported case of acute multiple arterial thrombosis following cisplatin in head and neck cancer. It is a dreaded complication and has a dismal prognosis if not promptly recognized and treated.
INTRODUCTION
Concurrent chemoradiation is the present-day standard of care for locally advanced inoperable oropharyngeal cancers including carcinoma base of tongue. 1 Concurrent cisplatin has the maximum benefit with an increase in survival by 6 .5% than radiation only treatment, especially at a dose of 100 mg/m 2 on D 1 , D 22 , D 43 of radiation. 1 It is now a well-established fact that addition of cisplatin also leads to added toxicity, both acute and late, which include enhanced radiation reactions, neurotoxicity, hematotoxicity, and nephrotoxicity. 2, 3 One of the exceedingly rare and devastating complications of cisplatin includes acute arterial thrombosis of the aorta. Prompt diagnosis and definitive treatment are imperative to decrease morbidity and mortality.
Cause of the rarity of this complication, there are very few reported cases in the literature. Most of the reported series include cisplatin in combination with other chemotherapeutic agents and in adenocarcinomas, which itself are notorious for hypercoagulability. Herein we describe an unusual case of carcinoma base of tongue, who had extensive arterial thrombosis following the first dose of the single-agent cisplatin used concurrently with radiotherapy. To the best of our knowledge this is the first reported case of acute multiple arterial thrombosis in a patient with squamous cell carcinoma of head and neck treated with cisplatin as a single agent. We also reviewed the clinical aspects and literature relating to this potentially fatal complication.
CASE REPORT
A 54-year-old, previously fit and healthy male smoker was diagnosed as having locally advanced squamous cell carcinoma of the base of tongue (T 4a N 1 M 0 ; ie, stage IV-A). He was started on radical chemoradiation, which was planned for 66 Gray (Gy) in 33 fractions over 6.5 weeks with concurrent cisplatin dosed at 100 mg/m 2 to be given on D 1 , D 22 , and D 43 . Three days after the first dose of cisplatin, he developed severe pain in the left leg and left thigh and calf claudication. Physical examination demonstrated diminished left femoral pulses with no bruits. Compression ultrasound did not reveal any evidence of deep venous thrombosis. Color Doppler revealed generalized thrombosis of the left femoral and tibeal arteries and the complete absence of flow through the popliteal and tibeal arteries. Following this he underwent peripheral CT angiography, which revealed mural plaques in the abdominal aorta, below the origin of mesenteric artery, causing significant irregular narrowing including the aortic bifurcation ( Figure 1 ). Also noted was complete occlusion of the left common iliac artery and the left saphenofemoral artery in the distal third of the thigh ( Figure 1B ). There was no radiologic evidence of extrinsic compression of the abdominal aorta by lymphadenopathies or masses. Subsequently, CT coronary angiography was also performed, which revealed soft plaques with moderate stenosis in the proximal segments of left anterior descending and right coronary artery. Dobutamine stress myocardial perfusion scintigraphy was unremarkable. Carotid color Doppler did not reveal any sign of carotid stenosis or occlusion.
He was managed conservatively initially, with unfractionated heparin followed by low-molecular-weight heparin during the course of radiation; subsequently, when the symptoms did not subside completely, he underwent femorofemoral crossover bypass graft surgery postradiotherapy. Further cycles of cisplatin were deferred. The patient was stable after treatment, and imaging 1 year later demonstrated stable thrombus.
DISCUSSION
We report a case of acute multiple arterial thrombosis in a patient with squamous cell carcinoma of the base of tongue following treatment with single-agent cisplatin used concurrently with radiation. This complication is exceedingly rare and devastating, with only few cases reported in the literature. Most of the cases reported to date have used cisplatin in combination with other chemotherapeutic agents for non-head and neck cancers, mostly adenocarcinomas. To the best of our knowledge, multiple arterial occlusions after the first cycle of singleagent cisplatin used concurrently with radiation in head and neck cancer have not been reported so far in the literature.
The increased risk of thrombosis in patients with active cancer has multiple causes. Although venous thrombosis is more common in patients with cancer than in the general population, chemotherapy-induced arterial thrombosis rarely has been reported. Patients with cancer are in a hypercoagulable state. The spectrum of hemostatic abnormalities ranges from abnormal coagulation tests in the absence of clinical manifestations to massive, fatal thromboembolism. 4 Thrombotic episodes may precede the diagnosis of malignancy by months or years and can present in 1 of the following ways 5 : (1) migratory superficial thrombophlebitis (Trousseau's syndrome); (2) idiopathic deep venous thrombosis and other venous thrombosis; (3) nonbacterial thrombotic endocarditis (marantic endocarditis); (4) disseminated intravascular coagulation (DIC); (5) thrombotic microangiopathy; and (6) arterial thrombosis (rare).
The thrombotic events may be predisposed due to cancer itself or due to the effect of chemotherapeutic agents. Cisplatin is known to increase the risk of thromboembolic events and is the agent most commonly implicated in patients with cancer and arterial thrombosis. 6, 7 The mechanism by which cisplatin triggers vascular events is unknown, but endothelial damage seems to play a major role. Other proposed hypotheses are cisplatin-induced elevation of plasma levels of von Willebrand factor, alteration of clotting cascade, thrombaxane-prostacyclin homeostatic disturbances, and stimulation of fibroblasts. [8] [9] [10] [11] [12] [13] Cisplatin is known to cause autonomic dysfunction and hypomagnesemia, which has been implicated in vascular events. 14 Hypomagnesemia is associated with vasospasm, but it has not been described as a cause of thrombosis of large vessels. The latter cause is unlikely in our index case since it is the protocol of our institute that all patients receiving cisplatin also receive prophylactic magnesium sulfate injection after every cycle.
In fact, most cases of cisplatin-induced arterial thrombosis described in the literature occurred in patients with at least 1 of the foregoing risk factors. 8,9,11 The patient described here had no chronic abnormalities in the abdominal aorta, such as aneurysm or atherosclerotic disease, nor enlarged lymph nodes or tumoral masses causing extrinsic compression of the abdominal aorta. In this case report, the potential risk factors for arterial thrombosis, aside from active malignancy and the use of cisplatin-based chemotherapy, was cigarette smoking.
There are few case reports of arterial thrombosis in testicular germ cell tumor post-BEP (bleomycin, etoposide, and cisplatin) regimen. 8, 11, 15, 16 In a retrospective study of patients with germ cell cancer receiving cisplatin-based combination chemotherapy, 15 of 179 patients (8.4%) experienced a thromboembolic event, with only a single fatality. 17 In a recent report, Fernandes et al 18 has reported 4 cases of aortic thrombosis following cisplatinbased multiagent chemotherapy in cancer rectosigmoid, non-small cell, and small cell lung cancer; all were adenocarcinomas.
In a recent retrospective analysis by Moore and colleagues, data from 932 patients treated with cisplatinbased chemotherapy were analyzed; of these, 18% experienced thromboembolic events, mainly venous thromboembolism. Less than 2% experienced arterial thrombosis. None of the patients had extensive multiple arterial involvement as in the index case.
Our case is unique in various aspects. First, there are no cases of multiple large vessel thromboses reported so far in the literature for head and neck cancers. Second, most already-reported cases include adenocarcinomas, which have a greater predisposition for thrombotic events (Trousseau's syndrome). Third, in most of the reported cases, cisplatin has been used in combination with other chemotherapeutic agents, whose effect might be additive for the complication. In the index case, cisplatin has been used as a single agent. Fourth, the event has occurred acutely within 7 days of the first cycle, unlike the most reported series where thrombosis occurred after only 3 or 4 cycles. Finally, the patient did not have any predisposing factor for the occurrence of an aortic thrombus before chemotherapy. Thus, we suggest that the hypercoagulable state occurred secondary to cisplatin causing aortic thrombosis.
Acute aortic thrombosis currently has no standardized treatment. Current guidelines recommend that, in patients who have acute arterial thromboemboli, initial therapy should include immediate systemic anticoagulation with unfractionated heparin followed by long-term vitamin K antagonists or long-term low-molecular-weight heparin. 19 The role of thromboprophylaxis in patients undergoing cisplatin-based chemotherapy is controversial. Established guidelines recommend prophylactic anticoagulation only for oncology patients in high-risk settings, such as hospitalization, major surgery, or postoperatively. Data on primary prevention of thrombosis in ambulatory patients with cancer receiving chemotherapy are limited with mixed results. The randomized PROTECT (Prophylaxis of Thromboembolism during Chemotherapy) trial have shown benefit of primary prevention with cisplatin-based combination chemotherapy in metastatic gastrointestinal or testicular cancers, 20 whereas the TOPIC I and II trials have failed to show any benefit. 21 None of the trials to date has addressed its role in locally advanced head and neck cancer receiving cisplatin as a single agent, concurrently with radiotherapy. Considering the rarity of arterial thrombotic complication in ambulatory patients with head and neck cancer following single-agent cisplatin, and concurrent chemoradiation being the standard of care for all locally advanced head and neck cancers, routine use of prophylactic anticoagulation is not currently recommended in this setting.
CONCLUSIONS
Acute aortic thrombosis is a dreaded complication and should be promptly recognized and treated. This is the first reported case of multiple arterial thrombosis involving aorta, femoro-poplitiel-tibeal and coronary arteries, following the first cycle of single-agent cisplatin for head and neck cancer used concurrently with radiation. All radiologists involved in the care of oncology patients should be aware of this rare but potentially fatal condition because prompt diagnosis and therapy increase the chances of a favorable outcome.
